|
|
Volumn 8, Issue 12, 2006, Pages 1435-
|
|
One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease: A position statement from the European Society of Gene Therapy (ESGT).
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARTICLE;
CASE REPORT;
CHRONIC GRANULOMATOUS DISEASE;
DISEASE COURSE;
EUROPE;
FATALITY;
GENE THERAPY;
GERMANY;
HUMAN;
INTESTINE PERFORATION;
MEDICAL SOCIETY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
SEPSIS;
SWITZERLAND;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DISEASE PROGRESSION;
EUROPE;
FATAL OUTCOME;
GENE THERAPY;
GERMANY;
GRANULOMATOUS DISEASE, CHRONIC;
HUMANS;
INTESTINAL PERFORATION;
SEPSIS;
SOCIETIES, MEDICAL;
SWITZERLAND;
|
|
EID: 70349302679
PISSN: 1099498X
EISSN: None
Source Type: Journal
DOI: 10.1002/jgm.991 Document Type: Article |
|
Times cited : (19)
|
|
References (0)
|